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ABSTRACT
Intravenous levodopa has been used in a multitude of research studies due to its
more predictable pharmacokinetics compared to the oral form, which is used
frequently as a treatment for Parkinson’s disease (PD). Levodopa is the precursor
for dopamine, and intravenous dopamine would strongly affect vascular tone, but
peripheral decarboxylase inhibitors are intended to block such effects. Pulse and
blood pressure, with orthostatic changes, were recorded before and after intravenous
levodopa or placebo—after oral carbidopa—in 13 adults with a chronic tic disorder
and 16 tic-free adult control subjects. Levodopa caused no statistically or clinically
significant changes in blood pressure or pulse. These data add to previous data that
support the safety of i.v. levodopa when given with adequate peripheral inhibition of
DOPA decarboxylase.
Subjects Cardiology, Evidence Based Medicine, Neurology, Pharmacology, Translational
Medicine
Keywords Carbidopa, Levodopa, Tourette syndrome, Heart rate, Randomized controlled trial,
Blood pressure, Intravenous
INTRODUCTION
The first therapeutic use of levodopa for Parkinson disease (PD) was by the intravenous
route (Birkmayer & Hornykiewicz, 1961; Birkmayer & Hornykiewicz, 1998; Hornykiewicz,
2010). Oral administration is preferred clinically due to ease of use, although intravenous
(i.v.) levodopa infusion has been favored in certain clinical circumstances (Chase, Engber &
Mouradian, 1994; Abramsky &Goldschmidt, 1974; Horai et al., 2002; Mizuno et al., 2009).
The i.v. route has advantages for some research purposes as well (Black et al., 2004; Black
et al., 2010; Black et al., 2015). However, levodopa is approved by the U.S. Food and Drug
Administration for treatment of PD and other parkinsonian conditions only in a tablet
formulation. In the U.S., giving an approved drug by another route for research purposes
may require an investigational new drug (IND) application if changing the route of admin-
istration “significantly increases the risks (or decreases the acceptability of the risks)” (ğ21
CFR 312.2(b)(iii): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.
cfm?fr=312.2). Some have assumed that this might hold for i.v. compared to oral levodopa.
In fact, however, numerous studies have reported on brief (<24 h) infusions or large
single-dose i.v. boluses, and i.v. levodopa has been tolerated approximately as well as oral
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levodopa (Abraham et al., 2015; Siddiqi et al., 2015). One study even deliberately attempted
to induce hallucinations by giving high-dose i.v. levodopa to patients at high risk, but
produced no hallucinations (Goetz et al., 1998). However, data on hemodynamic effects
of i.v. levodopa have been limited over the past 20 years, and such results have not yet
been quantitatively reported in the presence of a peripheral decarboxylase inhibitor
(Abraham et al., 2015; Siddiqi et al., 2015).
Here we provide quantitative data, from a double-blind, random-allocation crossover




Forty-four generally healthy adults (23 with Tourette syndrome or chronic motor
tic disorder [TS] and 21 tic-free healthy control [HC] subjects) enrolled in a study
investigating dopaminergic effects on cortical function during a working memory task
as measured by functional magnetic resonance imaging (ClinicalTrials.gov identifier
NCT00634556). The study was approved by the Human Research Protection Office (IRB)
of Washington University in St. Louis (project #05–0832, #201105100), and all subjects
provided written documentation of informed consent prior to participation. This study
was performed under FDA IND #69,745, Kevin J. Black, Sponsor-Investigator. After
the first 10 subjects had been enrolled, the FDA asked us to record orthostatic blood
pressure and pulse before and during the infusions. No subjects took any dopaminergic
or antidopaminergic medications at baseline, including levodopa, dopamine agonists,
or antipsychotics. Six subjects dropped out or were withdrawn from the imaging study
(claustrophobia 1, abnormal structural MRI 1, scheduling problems 2, vomiting 2).
Complete vital signs were still available for one of the two subjects who were excluded
from the imaging study due to vomiting, so these data were included. Therefore, 15 of the
44 subjects were not included in vital signs analysis (10 subjects enrolled before initiation
of vital sign collection, 5 subjects dropped out before full range of vital signs could be
collected), leaving 29 subjects for analysis.
Medications
No subjects were taking dopaminergic or antidopaminergic medications at baseline. All
subjects avoided caffeine, nicotine, and proteins starting at midnight before the morning
of the study. Water, juice, and other non-protein food items were allowed prior to study
initiation, but subjects had no oral intake during the study period. At least 1 h after taking
200 mg carbidopa by mouth, levodopa was given intravenously in a 2 mg/mL solution
according to the “final protocol” described in Black et al. (2003). Specifically, a loading
dose of 0.6426 mg/kg was given i.v. over 10 min followed by a maintenance infusion at
2.882× 10−5 mg/kg/min× (140 yr-age)/yr for an additional 90 min. A 35-year-old patient
weighing 70 kg would receive a total dose of 64 mg (in 32 mL of normal saline); an oral
dose of 150–200 mg would provide the same total absorbed dose, though over a slower
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time scale (Sasahara et al., 1980; Robertson et al., 1989; Kompoliti et al., 2002). The mean
peak levodopa plasma concentration (Cp) with this method was ∼2,350 ng/ml, and the
steady-state Cp was ∼600 ng/ml (Black et al., 2003). On a separate day at least 1 week
later, each patient received a placebo infusion after carbidopa. The order of the levodopa
and placebo infusions was balanced. Both placebo and levodopa infusions were initiated
between 8:00 AM and 10:00 AM on the study day. Study staff were blinded to the order of
infusions, so both infusions occurred at approximately the same time of day.
Measurements
Vital signs were measured for each patient before and after the infusion on each day. Each
vital sign measurement included heart rate, systolic blood pressure, and diastolic blood
pressure (P, SBP, DBP) measured when the subject had lain supine for at least 5 min,
and repeated after at least 1 min standing, a protocol that was approved by the FDA
reviewer. The method of blood pressure measurement was consistent between pre-infusion
and post-infusion measurements: most measurements were taken electronically, but
measurements by manual sphygmomanometry were conducted on a minority of study
days. At the end of the study, these measurements were available on both infusion days for
29 patients. Subjects and staff measuring vital signs were blind to infusion order.
After each infusion, subjects completed the Pittsburgh Side Effects Rating Scale (Pelham
Jr, 1993), a self-rated checklist of common psychotropic side effects in which scores range
between 0 and 57. Before and after each infusion, subjects completed a visual analog scale
(on a scale of 1–100) to rate light-headedness–dizziness, nausea–vomiting, sleepiness, and
overall health.
Statistical analysis
Means for each vital sign parameter were compared between levodopa treatment days and
placebo treatment days by paired t tests. For each parameter, within-subjects confidence
intervals were computed based on patients for whom the parameter was available for both
placebo and levodopa days (Morey, 2008). Pittsburgh Side Effects Rating Scale scores and
change in visual analog scale scores for adverse effects were compared similarly.
RESULTS
Fourteen patients received placebo infusion on the first study day and levodopa on the
second day, while 15 received the converse. All data were collected as intended with the
exception of a standing pulse for one subject and post-infusion standing blood pressure
for one patient after levodopa infusion and for one patient after placebo infusion. Baseline
clinical characteristics are summarized in Table 1.
No significant difference was found between vital sign parameters during levodopa
versus placebo infusions (Table 2, Fig. 1). Standing increased P and DBP, and the
magnitude of this change increased somewhat from earlier to later in the day, but none
of these changes differed between levodopa and placebo. The largest absolute orthostatic
increases in P, both of which were found on the post-infusion measurements, were 11.7
bpm on the placebo day and 12.3 bpm on the levodopa day. The largest absolute orthostatic
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Table 1 Baseline clinical characteristics of subjects.
Age (years) 32.7 ± 11.2
Weight (kg) 79.1 ± 12.4
Sex 21 M, 8 F
Concurrent antihypertensives 10.3%*
Concurrent dopaminergic medications 0%
Notes.
* Of the three patients taking antihypertensives, one was for hypertension; the other two were taking centrally acting
α2-adrenergic agonists for treatment of Tourette’s syndrome.
Table 2 Vital sign parameters after levodopa and placebo infusions. Means and 95% confidence
intervals are shown for individual vital sign parameters after levodopa and placebo infusions, for subjects
who had data on both days. No significant levodopa-placebo difference was found in any parameter.
Units for BP: mmHg; units for P: beats per minute.
Condition Number of pairs Levodopa (95% CI) Placebo (95% CI) p
SBP (supine) 29 118 (115, 122) 121 (118, 125) 0.16
SBP (standing) 27 117 (112, 122) 120 (115, 125) 0.19
SBP (orthostatic change) 27 −1 (−6, 4) −1 (−6, 4) 0.91
DBP (supine) 29 75 (72, 78) 74 (71, 77) 0.86
DBP (standing) 27 77 (72, 82) 82 (77, 87) 0.18
DBP (orthostatic change) 27 2 (−2, 7) 7 (2, 12) 0.20
P (supine) 29 62 (61, 64) 61 (59, 63) 0.34
P (standing) 28 75 (72, 78) 73 (70, 76) 0.35
P (orthostatic change) 28 13 (10, 16) 12 (9, 15) 0.65
Table 3 Self-reported side effects. Mean and 95% confidence intervals are shown for self-reported side
effects with levodopa and placebo infusions.
Parameter Placebo (95% CI) Levodopa (95% CI) p
Pittsburgh side effects rating scale 2.0 (1.2, 2.9) 3.0 (1.4, 3.8) 0.25
Change in VAS (light-headedeness) 0.0 (−2.1, 2.1) 3.0 (−1.1, 7.1) 0.26
Change in VAS (nausea) 0.7 (−0.8, 2.3) −0.2 (−3.7, 3.4) 0.67
Change in VAS (sleepiness) 2.8 (−3.1, 8.6) 4.9 (−0.9, 10.7) 0.88
Change in VAS (overall health) −1.8 (−6.2, 2.6) −1.7 (−8.6, 5.2) 0.88
increases in DBP, also found on the post-infusion measurements, were 7.4 mmHg in
the placebo group and 2.0 mmHg in the levodopa group (p = 0.20). For the differences
between levodopa and placebo for all vital sign parameters (supine P/SBP/DBP, standing
P/SBP/DBP, orthostatic change in P/SBP/DBP), paired p values ranged between 0.16 (for
supine SBP) and 0.92 (for standing SBP). Additionally, no significant difference was found
for adverse effect scales (Table 3).
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Figure 1 Orthostatic vital signs before and after levodopa infusion. No significant changes were
observed between IV levodopa or placebo days in (A) heart rate, (B) systolic blood pressure, or (C)
diastolic blood pressure. Values shown are mean ± S.D. for all data. (See Table 2 for means and 95%
confidence intervals from the paired analysis.)
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DISCUSSION
These data in generally healthy young adults further support more comprehensive data
from previous studies suggesting that i.v. levodopa, at a dose that produces biologically
meaningful effects on parkinsonism, does not meaningfully affect orthostatic vital signs
when it is given after adequate inhibition of DOPA decarboxylase. Previous studies
supporting this conclusion are reviewed elsewhere (Abraham et al., 2015), but here we
summarize the key data.
Even before the advent of peripheral decarboxylase inhibitors, large doses of i.v.
levodopa were observed to have minimal effects on blood pressure. Moorthy et al. (1972)
gave 100–200 mg levodopa i.v. over 10 min to 8 cardiac patients ages 40–77, and reported
slight increase in heart rate, aortic and pulmonary arterial pressures, cardiac output,
oxygen consumption, heart rate, and systolic and diastolic aortic and pulmonary arterial
pressure, along with a slight decrease in systemic arterial resistance; however, specific
data and statistical significances were not reported and there was no placebo group. Of
note, all of these parameters recovered 30 min after infusion and no subjective symptoms
were reported, so the authors concluded that intravenous levodopa was safe even in PD
patients with advanced cardiovascular disease (Moorthy et al., 1972). Bruno & Brigida
(1965) and Baldy-Moulinier et al. (1977) monitored pulse and BP at frequent intervals
after i.v. infusions of 2 mg/kg (140 mg) over 5 min and 125 mg in 15 min respectively, but
provided no quantitative data; the authors simply state that there was no change in arterial
BP (Baldy-Moulinier et al., 1977, p. 184) or that there were no significant clinical problems
with the infusion (Bruno& Brigida, 1965).
The non-neurological side effects of levodopa are further prevented or ameliorated by
carbidopa, a peripheral decarboxylase inhibitor whose purpose is to prevent levodopa
from being converted to dopamine in the peripheral circulation (Barbeau & Roy, 1976;
Cotzias, Papavasiliou & Gellene, 1969). Peripheral decarboxylase inhibitors revolutionized
the treatment of PD 45 years ago (Papavasiliou et al., 1972) by reducing autonomic and
gastrointestinal effects of oral levodopa, most commonly dose-related nausea, dizziness
or orthostatic hypotension. Smaller doses of peripheral decarboxylase inhibitors (25–50
mg of carbidopa) have minimal impact on the autonomic effects of intravenous levodopa
(Irwin et al., 1992), but the same occurs with oral levodopa after 50 mg of benserazide
(Noack et al., 2014), suggesting that the route of administration of leovodopa is not the key
difference.
By contrast, here a larger dose of carbidopa (200 mg), given early enough that
adequate absorption could occur before levodopa administration, effectively prevented
any autonomic effects. One might posit that these favorable results are due to the younger
sample without Parkinson disease, because hypotension has been observed with levodopa
(without PDIs) in several PD studies (Whitsett & Goldberg, 1972; Calne et al., 1970;
Se´nard et al., 1995; Haapaniemi et al., 2000; Bouhaddi et al., 2004; Wolf et al., 2006).
However, hypotension with levodopa in PD is also suppressed by larger doses of PDIs
(Mehagnoul-Schipper et al., 2001); similarly, with carbidopa dosed as in the present study
oral levodopa produced no mean change in cerebral blood flow (Hershey et al., 1998).
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Finally, a different brain imaging study in PD that dosed carbidopa similarly found no
significant differences in BP or P after vs. before i.v. levodopa (Black et al., 2010, and K
Black, 2010, unpublished data). Thus we ascribe the positive results in the present study to
the larger and earlier dosing of carbidopa.
Sedation is the most common central side effect of levodopa, and patients with
advanced PD also may experience dyskinesias, hallucinations, or confusion. More recently,
attention has also been given to gambling, paraphilias, and other disinhibited behavior
that emerges in a substantial minority of patients treated with dopamimetics (Black &
Friedman, 2006), but these complications are more common with synthetic dopamine
agonists and have been reported only after chronic treatment (Weintraub et al., 2010; Poletti
et al., 2013). We are unaware of any evidence that central side effects are more common
with intravenous levodopa than with oral levodopa.
Overall, these data further elucidate the safety profile of intravenous levodopa and
reaffirm that it causes no meaningful change in orthostatic vital signs when combined with
oral carbidopa at the dose and schedule used in the present study. This adds to prior data
showing an overall safety profile comparable to that of oral levodopa, and may help allevi-
ate some of the regulatory concerns regarding the use of intravenous levodopa in research.
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